Muramyl dipeptide induces NOD2-dependent Ly6Chigh monocyte recruitment to the lungs and protects against Influenza virus infection

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Coulombe, François ^a   Fiola, Stéphanie ^a   Akira, Shizuo ^b   Cormier, Yvon ^c   Gosselin, Jean ^a  

^a LAVAL UNIVERSITY   (Canada)

^b OSAKA UNIVERSITY   (Japan)

^c LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MURAMYL DIPEPTIDE; TUMOR NECROSIS FACTOR ALPHA; CARD15 PROTEIN, MOUSE; CCL2 PROTEIN, MOUSE; IMMUNOLOGICAL ADJUVANT; LY 6C ANTIGEN, MOUSE; LY ANTIGEN; LY-6C ANTIGEN, MOUSE; N ACETYLMURAMYLALANYL DEXTRO ISOGLUTAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL MIGRATION; CELL POPULATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; INFLUENZA; INFLUENZA VIRUS A; LUNG FUNCTION; MONOCYTE; MOUSE; NEUTROPHIL; NONHUMAN; TREATMENT RESPONSE; VIRUS LOAD; ANIMAL; CELL MOTION; DRUG EFFECT; GENETICS; LUNG; METABOLISM; MOUSE MUTANT; NEUTROPHIL CHEMOTAXIS; ORTHOMYXOVIRUS INFECTION; PATHOLOGY;

BACTERIA (MICROORGANISMS); INFLUENZA A VIRUS; IPS; MUS; ORTHOMYXOVIRIDAE;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, LY; CELL MOVEMENT; CHEMOKINE CCL2; INFLUENZA A VIRUS; LUNG; MICE; MICE, KNOCKOUT; MONOCYTES; NEUTROPHIL INFILTRATION; NEUTROPHILS; NOD2 SIGNALING ADAPTOR PROTEIN; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84860760507     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0036734     Document Type: Article

References (39)

1. Azuma I, Kishimoto S, Yamamura Y, Petit JF, (1971) Adjuvanticity of mycobacterial cell walls. Jpn J Microbiol 15: 193-197.
2. Ellouz F, Adam A, Ciorbaru R, Lederer E, (1974) Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives. Biochem Biophys Res Commun 59: 1317-1325.
3. Ikeda S, Negishi T, Nishimura C, (1985) Enhancement of non-specific resistance to viral infection by muramyldipeptide and its analogs. Antiviral Res 5: 207-215.
4. McLaughlin CA, Schwartzman SM, Horner BL, Jones GH, Moffatt JG, et al. (1980) Regression of tumors in guinea pigs after treatment with synthetic muramyl dipeptides and trehalose dimycolate. Science 208: 415-416.
5. Masihi KN, Brehmer W, Lange W, Ribi E, Schwartzman S, (1984) Protective effect of muramyl dipeptide analogs in combination with trehalose dimycolate against aerogenic influenza virus and Mycobacterium tuberculosis infections in mice. J Biol Response Mod 3: 663-671.
6. Bahr GM, Darcissac E, Bevec D, Dukor P, Chedid L, (1995) Immunopharmacological activities and clinical development of muramyl peptides with particular emphasis on murabutide. Int J Immunopharmacol 17: 117-131.
7. Azuma I, Otani T, (1994) Potentiation of host defense mechanism against infection by a cytokine inducer, an acyl-MDP derivative, MDP-Lys(L18) (romurtide) in mice and humans. Med Res Rev 14: 401-414.
8. Dzierzbicka K, Wardowska A, Trzonkowski P, (2011) Recent developments in the synthesis and biological activity of muramylpeptides. Curr Med Chem 18: 2438-2451.
9. Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, et al. (2003) Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 278: 8869-8872.
10. Kobayashi K, Inohara N, Hernandez LD, Galan JE, Nunez G, et al. (2002) RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature 416: 194-199.
11. Yang Y, Yin C, Pandey A, Abbott D, Sassetti C, et al. (2007) NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem 282: 36223-36229.
12. Pandey AK, Yang Y, Jiang Z, Fortune SM, Coulombe F, et al. (2009) NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog 5: e1000500.
13. Koerner I, Kochs G, Kalinke U, Weiss S, Staeheli P, (2007) Protective role of beta interferon in host defense against influenza A virus. J Virol 81: 2025-2030.
14. Szretter KJ, Gangappa S, Belser JA, Zeng H, Chen H, et al. (2009) Early control of H5N1 influenza virus replication by the type I interferon response in mice. J Virol 83: 5825-5834.
15. Sabbah A, Chang TH, Harnack R, Frohlich V, Tominaga K, et al. (2009) Activation of innate immune antiviral responses by Nod2. Nat Immunol 10: 1073-1080.
16. Kim YG, Kamada N, Shaw MH, Warner N, Chen GY, et al. (2011) The Nod2 Sensor Promotes Intestinal Pathogen Eradication via the Chemokine CCL2-Dependent Recruitment of Inflammatory Monocytes. Immunity.
17. Seo SU, Kwon HJ, Ko HJ, Byun YH, Seong BL, et al. (2011) Type I Interferon Signaling Regulates Ly6C Monocytes and Neutrophils during Acute Viral Pneumonia in Mice. PLoS Pathog 7: e1001304.
18. Masihi KN, Brehmer W, Lange W, Ribi E, (1983) Effects of mycobacterial fractions and muramyl dipeptide on the resistance of mice to aerogenic influenza virus infection. Int J Immunopharmacol 5: 403-410.
19. Chomel JJ, Simon-Lavoine N, Thouvenot D, Valette M, Choay J, et al. (1988) Prophylactic and therapeutic effects of murabutide in OF1 mice infected with influenza A/H3N2 (A/Texas/1/77) virus. J Biol Response Mod 7: 581-586.
20. Wyde PR, Six HR, Ambrose MW, Throop BJ, (1990) Muramyl peptides and polyinosinic-polycytodylic acid given to mice prior to influenza virus challenge reduces pulmonary disease and mortality. J Biol Response Mod 9: 98-102.
21. Dienz O, Rud JG, Eaton SM, Lanthier PA, Burg E, et al. (2012) Essential role of IL-6 in protection against H1N1 influenza virus by promoting neutrophil survival in the lung. Mucosal Immunol.
22. Damjanovic D, Divangahi M, Kugathasan K, Small CL, Zganiacz A, et al. (2011) Negative Regulation of Lung Inflammation and Immunopathology by TNF-alpha during Acute Influenza Infection. Am J Pathol.
23. Bermejo-Martin JF, Martin-Loeches I, Rello J, Anton A, Almansa R, et al. (2010) Host adaptive immunity deficiency in severe pandemic influenza. Crit Care 14: R167.
24. Moltedo B, Lopez CB, Pazos M, Becker MI, Hermesh T, et al. (2009) Cutting edge: stealth influenza virus replication precedes the initiation of adaptive immunity. J Immunol 183: 3569-3573.
25. Shi C, Pamer EG, (2011) Monocyte recruitment during infection and inflammation. Nat Rev Immunol 11: 762-774.
26. Auffray C, Sieweke MH, Geissmann F, (2009) Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 27: 669-692.
27. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, et al. (2008) Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 82: 335-345.
28. Coulombe F, Divangahi M, Veyrier F, de Leseleuc L, Gleason JL, et al. (2009) Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med 206: 1709-1716.
29. Hoeve MA, Nash AA, Jackson D, Randall RE, Dransfield I, (2012) Influenza virus A infection of human monocyte and macrophage subpopulations reveals increased susceptibility associated with cell differentiation. PLoS One 7: e29443.
30. Dawson TC, Beck MA, Kuziel WA, Henderson F, Maeda N, (2000) Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus. Am J Pathol 156: 1951-1959.
31. Aldridge JR Jr, Moseley CE, Boltz DA, Negovetich NJ, Reynolds C, et al. (2009) TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 106: 5306-5311.
32. Sorbara MT, Philpott DJ, (2011) Peptidoglycan: a critical activator of the mammalian immune system during infection and homeostasis. Immunol Rev 243: 40-60.
33. Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, et al. (2008) Nod2-dependent Th2 polarization of antigen-specific immunity. J Immunol 181: 7925-7935.
34. Davis KM, Nakamura S, Weiser JN, (2011) Nod2 sensing of lysozyme-digested peptidoglycan promotes macrophage recruitment and clearance of S. pneumoniae colonization in mice. J Clin Invest 121: 3666-3676.
35. De La Tribonniere X, Mouton Y, Vidal V, Darcissac E, Sissoko D, et al. (2003) A phase I study of a six-week cycle of immunotherapy with Murabutide in HIV-1 patients naive to antiretrovirals. Med Sci Monit 9: PI43-50.
36. Bahr GM, De La Tribonniere X, Darcissac E, Ajana F, Bocket L, et al. (2003) Clinical and immunological effects of a 6 week immunotherapy cycle with murabutide in HIV-1 patients with unsuccessful long-term antiretroviral treatment. J Antimicrob Chemother 51: 1377-1388.
37. Bahr GM, (2003) Non-specific immunotherapy of HIV-1 infection: potential use of the synthetic immunodulator murabutide. J Antimicrob Chemother 51: 5-8.
38. Ando K, Mori K, Corradini N, Redini F, Heymann D, (2011) Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother 12: 285-292.
39. Gaudreault E, Gosselin J, (2008) Leukotriene B4 induces release of antimicrobial peptides in lungs of virally infected mice. J Immunol 180: 6211-6221.